Chung-Han Lee, MD, PhD

Rana McKay, MD

GU Oncology Now

<p>Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, and Rana McKay, MD, University of California, San Diego Moores Cancer Center, discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


Drs. Lee, McKay on KEYNOTE-B61 for Non-Clear Cell RCC

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe